Sanofi is allowing open access from Jan. 1 on out

Sanofi's all up for open access--as long as it can keep its past records under lock and key. Following in the footsteps of Big Pharma counterparts like GlaxoSmithKline ($GSK), Sanofi ($SNY) says it will provide data, documents and reports on studies used to support U.S. and European applications on drugs approved after Jan. 1 of this year. Additionally, it will work with regulators to deliver clinical study subjects simple explanations of their individual results. The move coincides with the joint principles on data sharing adopted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA), which also went into effect on the first day of this year. Both groups have been battling a proposal from the European Medicines Agency (EMA) that would mandate more data disclosure than the industry might like. Story

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.